G-CSF Biosimilars Industry Research Report 2025
Description
Summary
According to APO Research, the global G-CSF Biosimilars market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of G-CSF Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, GlaxoSmithKline, Bayer and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF Biosimilars.
The report will help the G-CSF Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The G-CSF Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global G-CSF Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
G-CSF Biosimilars Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck & Co.
Roche
Pfizer
GlaxoSmithKline
Bayer
Amgen
AbbVie
AstraZeneca
Gilead Science
G-CSF Biosimilars Segment by Type
Insulin
Human Growth Hormone
Granulocyte-Colony Stimulating Factor
Interferon
Monoclonal Antibodies
Erythropoietin
G-CSF Biosimilars Segment by Application
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Blood Disorders
Oncology Diseases
G-CSF Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global G-CSF Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of G-CSF Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of G-CSF Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of G-CSF Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global G-CSF Biosimilars market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for G-CSF Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of G-CSF Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, GlaxoSmithKline, Bayer and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF Biosimilars.
The report will help the G-CSF Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The G-CSF Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global G-CSF Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
G-CSF Biosimilars Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck & Co.
Roche
Pfizer
GlaxoSmithKline
Bayer
Amgen
AbbVie
AstraZeneca
Gilead Science
G-CSF Biosimilars Segment by Type
Insulin
Human Growth Hormone
Granulocyte-Colony Stimulating Factor
Interferon
Monoclonal Antibodies
Erythropoietin
G-CSF Biosimilars Segment by Application
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Blood Disorders
Oncology Diseases
G-CSF Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global G-CSF Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of G-CSF Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of G-CSF Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of G-CSF Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
122 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global G-CSF Biosimilars Market Size (2020-2031)
- 2.2.2 Global G-CSF Biosimilars Sales (2020-2031)
- 2.2.3 Global G-CSF Biosimilars Market Average Price (2020-2031)
- 2.3 G-CSF Biosimilars by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Insulin
- 2.3.3 Human Growth Hormone
- 2.3.4 Granulocyte-Colony Stimulating Factor
- 2.3.5 Interferon
- 2.3.6 Monoclonal Antibodies
- 2.3.7 Erythropoietin
- 2.4 G-CSF Biosimilars by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Chronic And Autoimmune Diseases
- 2.4.3 Growth Hormone Deficiencies
- 2.4.4 Blood Disorders
- 2.4.5 Oncology Diseases
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global G-CSF Biosimilars Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global G-CSF Biosimilars Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global G-CSF Biosimilars Revenue of Manufacturers (2020-2025)
- 3.4 Global G-CSF Biosimilars Average Price by Manufacturers (2020-2025)
- 3.5 Global G-CSF Biosimilars Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of G-CSF Biosimilars, Product Type & Application
- 3.8 Global Manufacturers of G-CSF Biosimilars, Established Date
- 3.9 Global G-CSF Biosimilars Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Sanofi G-CSF Biosimilars Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Johnson & Johnson G-CSF Biosimilars Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Novartis G-CSF Biosimilars Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck & Co.
- 4.4.1 Merck & Co. Company Information
- 4.4.2 Merck & Co. Business Overview
- 4.4.3 Merck & Co. G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Merck & Co. G-CSF Biosimilars Product Portfolio
- 4.4.5 Merck & Co. Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Roche G-CSF Biosimilars Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Pfizer G-CSF Biosimilars Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 GlaxoSmithKline G-CSF Biosimilars Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Bayer
- 4.8.1 Bayer Company Information
- 4.8.2 Bayer Business Overview
- 4.8.3 Bayer G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Bayer G-CSF Biosimilars Product Portfolio
- 4.8.5 Bayer Recent Developments
- 4.9 Amgen
- 4.9.1 Amgen Company Information
- 4.9.2 Amgen Business Overview
- 4.9.3 Amgen G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Amgen G-CSF Biosimilars Product Portfolio
- 4.9.5 Amgen Recent Developments
- 4.10 AbbVie
- 4.10.1 AbbVie Company Information
- 4.10.2 AbbVie Business Overview
- 4.10.3 AbbVie G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 AbbVie G-CSF Biosimilars Product Portfolio
- 4.10.5 AbbVie Recent Developments
- 4.11 AstraZeneca
- 4.11.1 AstraZeneca Company Information
- 4.11.2 AstraZeneca Business Overview
- 4.11.3 AstraZeneca G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 AstraZeneca G-CSF Biosimilars Product Portfolio
- 4.11.5 AstraZeneca Recent Developments
- 4.12 Gilead Science
- 4.12.1 Gilead Science Company Information
- 4.12.2 Gilead Science Business Overview
- 4.12.3 Gilead Science G-CSF Biosimilars Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Gilead Science G-CSF Biosimilars Product Portfolio
- 4.12.5 Gilead Science Recent Developments
- 5 Global G-CSF Biosimilars Market Scenario by Region
- 5.1 Global G-CSF Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global G-CSF Biosimilars Sales by Region: 2020-2031
- 5.2.1 Global G-CSF Biosimilars Sales by Region: 2020-2025
- 5.2.2 Global G-CSF Biosimilars Sales by Region: 2026-2031
- 5.3 Global G-CSF Biosimilars Revenue by Region: 2020-2031
- 5.3.1 Global G-CSF Biosimilars Revenue by Region: 2020-2025
- 5.3.2 Global G-CSF Biosimilars Revenue by Region: 2026-2031
- 5.4 North America G-CSF Biosimilars Market Facts & Figures by Country
- 5.4.1 North America G-CSF Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America G-CSF Biosimilars Sales by Country (2020-2031)
- 5.4.3 North America G-CSF Biosimilars Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe G-CSF Biosimilars Market Facts & Figures by Country
- 5.5.1 Europe G-CSF Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe G-CSF Biosimilars Sales by Country (2020-2031)
- 5.5.3 Europe G-CSF Biosimilars Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific G-CSF Biosimilars Market Facts & Figures by Country
- 5.6.1 Asia Pacific G-CSF Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific G-CSF Biosimilars Sales by Country (2020-2031)
- 5.6.3 Asia Pacific G-CSF Biosimilars Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America G-CSF Biosimilars Market Facts & Figures by Country
- 5.7.1 South America G-CSF Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America G-CSF Biosimilars Sales by Country (2020-2031)
- 5.7.3 South America G-CSF Biosimilars Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa G-CSF Biosimilars Market Facts & Figures by Country
- 5.8.1 Middle East and Africa G-CSF Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa G-CSF Biosimilars Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa G-CSF Biosimilars Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global G-CSF Biosimilars Sales by Type (2020-2031)
- 6.1.1 Global G-CSF Biosimilars Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global G-CSF Biosimilars Sales Market Share by Type (2020-2031)
- 6.2 Global G-CSF Biosimilars Revenue by Type (2020-2031)
- 6.2.1 Global G-CSF Biosimilars Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global G-CSF Biosimilars Revenue Market Share by Type (2020-2031)
- 6.3 Global G-CSF Biosimilars Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global G-CSF Biosimilars Sales by Application (2020-2031)
- 7.1.1 Global G-CSF Biosimilars Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global G-CSF Biosimilars Sales Market Share by Application (2020-2031)
- 7.2 Global G-CSF Biosimilars Revenue by Application (2020-2031)
- 7.2.1 Global G-CSF Biosimilars Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global G-CSF Biosimilars Revenue Market Share by Application (2020-2031)
- 7.3 Global G-CSF Biosimilars Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 G-CSF Biosimilars Value Chain Analysis
- 8.1.1 G-CSF Biosimilars Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 G-CSF Biosimilars Production Mode & Process
- 8.2 G-CSF Biosimilars Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 G-CSF Biosimilars Distributors
- 8.2.3 G-CSF Biosimilars Customers
- 9 Global G-CSF Biosimilars Analyzing Market Dynamics
- 9.1 G-CSF Biosimilars Industry Trends
- 9.2 G-CSF Biosimilars Industry Drivers
- 9.3 G-CSF Biosimilars Industry Opportunities and Challenges
- 9.4 G-CSF Biosimilars Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global G-CSF Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global G-CSF Biosimilars Sales (K Units) of Manufacturers (2020-2025)
- Table 7. Global G-CSF Biosimilars Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global G-CSF Biosimilars Revenue of Manufacturers (2020-2025)
- Table 9. Global G-CSF Biosimilars Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market G-CSF Biosimilars Average Price (US$/Unit) of Manufacturers (2020-2025)
- Table 11. Global G-CSF Biosimilars Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of G-CSF Biosimilars, Product Type & Application
- Table 14. Global G-CSF Biosimilars Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global G-CSF Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Sanofi Company Information
- Table 19. Sanofi Business Overview
- Table 20. Sanofi G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 21. Sanofi G-CSF Biosimilars Product Portfolio
- Table 22. Sanofi Recent Developments
- Table 23. Johnson & Johnson Company Information
- Table 24. Johnson & Johnson Business Overview
- Table 25. Johnson & Johnson G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 26. Johnson & Johnson G-CSF Biosimilars Product Portfolio
- Table 27. Johnson & Johnson Recent Developments
- Table 28. Novartis Company Information
- Table 29. Novartis Business Overview
- Table 30. Novartis G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 31. Novartis G-CSF Biosimilars Product Portfolio
- Table 32. Novartis Recent Developments
- Table 33. Merck & Co. Company Information
- Table 34. Merck & Co. Business Overview
- Table 35. Merck & Co. G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 36. Merck & Co. G-CSF Biosimilars Product Portfolio
- Table 37. Merck & Co. Recent Developments
- Table 38. Roche Company Information
- Table 39. Roche Business Overview
- Table 40. Roche G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 41. Roche G-CSF Biosimilars Product Portfolio
- Table 42. Roche Recent Developments
- Table 43. Pfizer Company Information
- Table 44. Pfizer Business Overview
- Table 45. Pfizer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 46. Pfizer G-CSF Biosimilars Product Portfolio
- Table 47. Pfizer Recent Developments
- Table 48. GlaxoSmithKline Company Information
- Table 49. GlaxoSmithKline Business Overview
- Table 50. GlaxoSmithKline G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 51. GlaxoSmithKline G-CSF Biosimilars Product Portfolio
- Table 52. GlaxoSmithKline Recent Developments
- Table 53. Bayer Company Information
- Table 54. Bayer Business Overview
- Table 55. Bayer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 56. Bayer G-CSF Biosimilars Product Portfolio
- Table 57. Bayer Recent Developments
- Table 58. Amgen Company Information
- Table 59. Amgen Business Overview
- Table 60. Amgen G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 61. Amgen G-CSF Biosimilars Product Portfolio
- Table 62. Amgen Recent Developments
- Table 63. AbbVie Company Information
- Table 64. AbbVie Business Overview
- Table 65. AbbVie G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 66. AbbVie G-CSF Biosimilars Product Portfolio
- Table 67. AbbVie Recent Developments
- Table 68. AstraZeneca Company Information
- Table 69. AstraZeneca Business Overview
- Table 70. AstraZeneca G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 71. AstraZeneca G-CSF Biosimilars Product Portfolio
- Table 72. AstraZeneca Recent Developments
- Table 73. Gilead Science Company Information
- Table 74. Gilead Science Business Overview
- Table 75. Gilead Science G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
- Table 76. Gilead Science G-CSF Biosimilars Product Portfolio
- Table 77. Gilead Science Recent Developments
- Table 78. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 79. Global G-CSF Biosimilars Sales by Region (2020-2025) & (K Units)
- Table 80. Global G-CSF Biosimilars Sales Market Share by Region (2020-2025)
- Table 81. Global G-CSF Biosimilars Sales by Region (2026-2031) & (K Units)
- Table 82. Global G-CSF Biosimilars Sales Market Share by Region (2026-2031)
- Table 83. Global G-CSF Biosimilars Revenue by Region (2020-2025) & (US$ Million)
- Table 84. Global G-CSF Biosimilars Revenue Market Share by Region (2020-2025)
- Table 85. Global G-CSF Biosimilars Revenue by Region (2026-2031) & (US$ Million)
- Table 86. Global G-CSF Biosimilars Revenue Market Share by Region (2026-2031)
- Table 87. North America G-CSF Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 88. North America G-CSF Biosimilars Sales by Country (2020-2025) & (K Units)
- Table 89. North America G-CSF Biosimilars Sales by Country (2026-2031) & (K Units)
- Table 90. North America G-CSF Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 91. North America G-CSF Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 92. Europe G-CSF Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. Europe G-CSF Biosimilars Sales by Country (2020-2025) & (K Units)
- Table 94. Europe G-CSF Biosimilars Sales by Country (2026-2031) & (K Units)
- Table 95. Europe G-CSF Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 96. Europe G-CSF Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Asia Pacific G-CSF Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 98. Asia Pacific G-CSF Biosimilars Sales by Country (2020-2025) & (K Units)
- Table 99. Asia Pacific G-CSF Biosimilars Sales by Country (2026-2031) & (K Units)
- Table 100. Asia Pacific G-CSF Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 101. Asia Pacific G-CSF Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 102. South America G-CSF Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 103. South America G-CSF Biosimilars Sales by Country (2020-2025) & (K Units)
- Table 104. South America G-CSF Biosimilars Sales by Country (2026-2031) & (K Units)
- Table 105. South America G-CSF Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 106. South America G-CSF Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 107. Middle East and Africa G-CSF Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. Middle East and Africa G-CSF Biosimilars Sales by Country (2020-2025) & (K Units)
- Table 109. Middle East and Africa G-CSF Biosimilars Sales by Country (2026-2031) & (K Units)
- Table 110. Middle East and Africa G-CSF Biosimilars Revenue by Country (2020-2025) & (US$ Million)
- Table 111. Middle East and Africa G-CSF Biosimilars Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Global G-CSF Biosimilars Sales by Type (2020-2025) & (K Units)
- Table 113. Global G-CSF Biosimilars Sales by Type (2026-2031) & (K Units)
- Table 114. Global G-CSF Biosimilars Sales Market Share by Type (2020-2025)
- Table 115. Global G-CSF Biosimilars Sales Market Share by Type (2026-2031)
- Table 116. Global G-CSF Biosimilars Revenue by Type (2020-2025) & (US$ Million)
- Table 117. Global G-CSF Biosimilars Revenue by Type (2026-2031) & (US$ Million)
- Table 118. Global G-CSF Biosimilars Revenue Market Share by Type (2020-2025)
- Table 119. Global G-CSF Biosimilars Revenue Market Share by Type (2026-2031)
- Table 120. Global G-CSF Biosimilars Price by Type (2020-2025) & (US$/Unit)
- Table 121. Global G-CSF Biosimilars Price by Type (2026-2031) & (US$/Unit)
- Table 122. Global G-CSF Biosimilars Sales by Application (2020-2025) & (K Units)
- Table 123. Global G-CSF Biosimilars Sales by Application (2026-2031) & (K Units)
- Table 124. Global G-CSF Biosimilars Sales Market Share by Application (2020-2025)
- Table 125. Global G-CSF Biosimilars Sales Market Share by Application (2026-2031)
- Table 126. Global G-CSF Biosimilars Revenue by Application (2020-2025) & (US$ Million)
- Table 127. Global G-CSF Biosimilars Revenue by Application (2026-2031) & (US$ Million)
- Table 128. Global G-CSF Biosimilars Revenue Market Share by Application (2020-2025)
- Table 129. Global G-CSF Biosimilars Revenue Market Share by Application (2026-2031)
- Table 130. Global G-CSF Biosimilars Price by Application (2020-2025) & (US$/Unit)
- Table 131. Global G-CSF Biosimilars Price by Application (2026-2031) & (US$/Unit)
- Table 132. Key Raw Materials
- Table 133. Raw Materials Key Suppliers
- Table 134. G-CSF Biosimilars Distributors List
- Table 135. G-CSF Biosimilars Customers List
- Table 136. G-CSF Biosimilars Industry Trends
- Table 137. G-CSF Biosimilars Industry Drivers
- Table 138. G-CSF Biosimilars Industry Restraints
- Table 139. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. G-CSF Biosimilars Product Image
- Figure 5. Global G-CSF Biosimilars Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global G-CSF Biosimilars Market Size (2020-2031) & (US$ Million)
- Figure 7. Global G-CSF Biosimilars Sales (2020-2031) & (K Units)
- Figure 8. Global G-CSF Biosimilars Average Price (US$/Unit) & (2020-2031)
- Figure 9. Insulin Product Image
- Figure 10. Human Growth Hormone Product Image
- Figure 11. Granulocyte-Colony Stimulating Factor Product Image
- Figure 12. Interferon Product Image
- Figure 13. Monoclonal Antibodies Product Image
- Figure 14. Erythropoietin Product Image
- Figure 15. Chronic And Autoimmune Diseases Product Image
- Figure 16. Growth Hormone Deficiencies Product Image
- Figure 17. Blood Disorders Product Image
- Figure 18. Oncology Diseases Product Image
- Figure 19. Global G-CSF Biosimilars Revenue Share by Manufacturers in 2024
- Figure 20. Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
- Figure 21. Global Top 5 and 10 G-CSF Biosimilars Players Market Share by Revenue in 2024
- Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 23. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 24. Global G-CSF Biosimilars Sales by Region in 2024
- Figure 25. Global G-CSF Biosimilars Revenue by Region in 2024
- Figure 26. North America G-CSF Biosimilars Market Size by Country in 2024
- Figure 27. North America G-CSF Biosimilars Sales Market Share by Country (2020-2031)
- Figure 28. North America G-CSF Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 29. United States G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 30. Canada G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. Europe G-CSF Biosimilars Market Size by Country in 2024
- Figure 32. Europe G-CSF Biosimilars Sales Market Share by Country (2020-2031)
- Figure 33. Europe G-CSF Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 34. Germany G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. France G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. U.K. G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Italy G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Netherlands G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Asia Pacific G-CSF Biosimilars Market Size by Country in 2024
- Figure 40. Asia Pacific G-CSF Biosimilars Sales Market Share by Country (2020-2031)
- Figure 41. Asia Pacific G-CSF Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 42. China G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. Japan G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. South Korea G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. India G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. Australia G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. China Taiwan G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Southeast Asia G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. South America G-CSF Biosimilars Market Size by Country in 2024
- Figure 51. South America G-CSF Biosimilars Sales Market Share by Country (2020-2031)
- Figure 52. South America G-CSF Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 53. Mexico G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 54. Brazil G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Argentina G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Middle East and Africa G-CSF Biosimilars Market Size by Country in 2024
- Figure 57. Middle East and Africa G-CSF Biosimilars Sales Market Share by Country (2020-2031)
- Figure 58. Middle East and Africa G-CSF Biosimilars Revenue Market Share by Country (2020-2031)
- Figure 59. Turkey G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 60. Saudi Arabia G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 61. UAE G-CSF Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. Global G-CSF Biosimilars Sales Market Share by Type (2020-2031)
- Figure 63. Global G-CSF Biosimilars Revenue Market Share by Type (2020-2031)
- Figure 64. Global G-CSF Biosimilars Price (US$/Unit) by Type (2020-2031)
- Figure 65. Global G-CSF Biosimilars Sales Market Share by Application (2020-2031)
- Figure 66. Global G-CSF Biosimilars Revenue Market Share by Application (2020-2031)
- Figure 67. Global G-CSF Biosimilars Price (US$/Unit) by Application (2020-2031)
- Figure 68. G-CSF Biosimilars Value Chain
- Figure 69. G-CSF Biosimilars Production Mode & Process
- Figure 70. Direct Comparison with Distribution Share
- Figure 71. Distributors Profiles
- Figure 72. G-CSF Biosimilars Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
